SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934

3003 ~~June~~July, 2006

Cambridge Antibody Technology Group PLC
(Translation of Registrant’s Name Into English)

Milstein Building, Granta Park, Cambridge, CB1 6GH, England
(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-

Form 20-F ____X____ Form 40-F ________

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2 (b) under the Securities Exchange Act of 193

Yes _________ No ____X_____

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2 (b): 82-___________

EXHIBIT INDEX

This filing contains the following exhibits.

EXHIBIT DESCRIPTION

99.1 ~~Holding(s)~~Directorate inChange ~~Company~~ dated 3003 ~~June~~July, 2006

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: 3003 ~~June~~July, 2006 Cambridge Antibody Technology Group PLC

                                                                                                                                                                 By: /s/ John Aston
                                                                                                                                                                 Name: John Aston
                                                                                                                                                                 Title: Chief Financial Officer

EXHIBIT 99.1

                   NOTIFICATION3 OFJuly MAJOR INTERESTS IN SHARES2006



1.                Cambridge NameAntibody ofTechnology company



CAMBRIDGEGroup ANTIBODYplc TECHNOLOGY GROUP PLC("CAT")



2.CAT Name(LSE: ofCAT; shareholderNASDAQ: havingCATG) aannounces major interest



ASTRAZENECA UK LIMITED



3. Please state whether notification indicates that itwith iseffect infrom respect30 ofJune holding
of2006, the shareholder named in 2 above or in respect of a non-beneficial interestPeter
orChambre, inJohn the case of an individual holder if it is a holding of that person's
spouse or children under the age of 18



ASTRAZENECA UK LIMITED       NOT DISCLOSED



4. Name of the registered holder(s) andAston, ifDiane more than one holderMellett, thePaul number of
shares held by each of them


15Nicholson,817,983      ASTRAZENECA UKAke LIMITED
178Stavling,607         GREENWOOD NOMINEES LIMITEDChristopher
11Marshall,962          DR PAULPeter NICHOLSON


32Ringrose,109,070      REPRESENTING ACCEPTANCESJohn OFStocker THEand OFFERJohn ANDBrown RECENT
                PURCHASEShave TOresigned BEas REGISTERED IN THE NAME OF ASTRAZENECA UK LIMITEDdirectors




5. Number of sharesthe / amount of stock acquired



15,917,983



6Company. PercentageWith ofeffect issuedfrom class



29.92%



7.30 NumberJune of2006, sharesthe /Company amountalso ofannounces stockthat disposedJ



N/A



8.W PercentageHoskins ofhas issuedresigned class



N/A



9.as ClassCompany ofSecretary security



ORDINARYand 10that PENCEG SHARES



10.H DateR ofMusker transaction



NOThas DISCLOSEDbeen

11.appointed DateCompany company informed



29 JUNE 2006



12Secretary. Total holding following this notification



48,117,622



13.For Totalfurther percentage holding of issued class following this notification



90.44%



14. Any additional information



NONE



15. Nameplease of contact and telephone number for queries:



JUSTINRowena HOSKINS 01223 898589



16. Name and signature of authorised company official responsible for making
this notification



JUSTIN HOSKINSGardner, COMPANYDirector SECRETARY



Date of notification



30Corporate JUNE 2006Communications



The+44 FSA does not give any express or implied warranty as to the accuracy of this
document or material and does not accept any liability for error or omission.
The FSA is not liable for any damages (including, without limitation, damages
for loss of business or loss of profits0) arising1223 in471 contract, tort or otherwise471
from the use of or inability to use this document, or any material contained in
it, or from any action or decision taken as a result of using this document or
any such material.

Filing Compare · CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC